ELDN: Updated Islet Cell Transplant Data Remains Encouraging For Tegoprubart; 12/12 Type 1 Diabetes Patients Achieve Insulin Independence

Research evidence excerpt

ELDN: Updated Islet Cell Transplant Data Remains Encouraging For Tegoprubart; 12/12 Type 1 Diabetes Patients Achieve Insulin Independence

FLASH NOTE

June 8, 2026

Vamil Divan, M.D. vamil.divan@guggenheimpartners.com ELDN: Updated Islet Cell Transplant Data Remains

212 823 6543 Encouraging For Tegoprubart; 12/12 Type 1 Diabetes

Edouard Mullarky, Ph.D.

edouard.mullarky@guggenheimpartners.com Patients Achieve Insulin Independence

212 518 9579

Arseniy Shabashvili Key Message: ELDN reported updated data this weekend at the American Diabetes

arseniy.shabashvili@guggenheimpartners.com Association (ADA) Meeting from an investigator-initiated trial (IIT) in patients with type 1 212 699 1971

diabetes who have undergone allogeneic islet cell transplantation (ICT). The study now

Daniel Krizay, Ph.D. reports data for 12 patients (versus 10 patients in the prior March update, link to our past

daniel.krizay@guggenheimpartners.com note here) and remain inline with encouraging prior disclosures. All 12 of the patients

212 823 6561 in the study are reported to have achieved insulin independence with HbA1c levels

below the 6.5% threshold reaching a mean of ~5.4% at the most recent measurement, a

~2.6% average improvement from baseline HbA1c. For patients in the study, median and

ELDN maximumIn addition,post-transplantno patients reportedfollow-upsevereperiodhypoglycemicis now up to 8episodesand 22 months,post-transplant.respectively.The

Eledon Pharmaceuticals, Inc. company's release also notes higher levels of post-transplant islet engraftment were

Sector: Biotechnology observed with tegoprubart-based immunosuppression regimen compared to historical

results seen with tacrolimus-based regimens at the IIT center. The release further notes